ASCO: Vepdegestrant ups survival in ER+, HER2− advanced breast cancer with ESR1 mutations

Published Date: 03 Jun 2025

For patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, the oral proteolysis-targeting chimera ER degrader, vepdegestrant, leads to significantly ...

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Junk Food & Prostate Cancer; 'Office' Star's Stage IV Diagnosis; New Cancer Cluster?

2.

Inconclusive BRCA Results Linked to Higher BC Risk

3.

TCL1A Protein Identified as Predictor of Blinatumomab Response in Relapsed B-ALL

4.

PSA Testing Is Not Enough for Another Candidate for Prostate Cancer Screening.

5.

Injecting PD-1 Drug Directly Into Oral Precancers Shrinks Lesions


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot